Have a feature idea you'd love to see implemented?
Let us know!
ICCC Immucell Corp
Price (delayed)
$3.66
Market cap
$32.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.5
Enterprise value
$44.34M
ImmuCell Corporation's purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate
Highlights
ICCC's quick ratio has surged by 90% since the previous quarter and by 18% year-on-year
ICCC's gross profit has soared by 77% YoY and by 5% QoQ
Key stats
What are the main financial stats of ICCC
Market
Valuations
Earnings
Shares outstanding
8.91M
Market cap
$32.62M
Enterprise value
$44.34M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.09
Price to sales (P/S)
1.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.86
Revenue
$23.84M
EBIT
-$3.81M
EBITDA
-$1.12M
Free cash flow
-$708,470
Per share
Balance sheet
Liquidity
EPS
-$0.5
Free cash flow per share
-$0.09
Book value per share
$3.37
Revenue per share
$2.92
TBVPS
$5.43
Total assets
$44.45M
Total liabilities
$18.04M
Debt
$15.53M
Equity
$26.41M
Working capital
$9.42M
Debt to equity
0.59
Current ratio
3.11
Quick ratio
1.37
Net debt/EBITDA
-10.49
Margins
Efficiency
Dividend
EBITDA margin
-4.7%
Gross margin
26.7%
Net margin
-16%
Operating margin
-13.7%
Return on assets
-8.8%
Return on equity
-15.3%
Return on invested capital
-7.2%
Return on capital employed
-9.5%
Return on sales
-16%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ICCC stock price
How has the Immucell stock price performed over time
Intraday
1.67%
1 week
1.67%
1 month
3.1%
1 year
-20.43%
YTD
-28.09%
QTD
0.83%
Financial performance
How have Immucell's revenue and profit performed over time
Revenue
$23.84M
Gross profit
$6.37M
Operating income
-$3.27M
Net income
-$3.81M
Gross margin
26.7%
Net margin
-16%
ICCC's gross profit has soared by 77% YoY and by 5% QoQ
The operating margin has surged by 65% year-on-year and by 18% since the previous quarter
Immucell's net margin has soared by 59% YoY and by 8% from the previous quarter
The operating income has grown by 49% year-on-year and by 16% since the previous quarter
Growth
What is Immucell's growth rate over time
Valuation
What is Immucell stock price valuation
P/E
N/A
P/B
1.09
P/S
1.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.86
ICCC's EPS is up by 38% year-on-year and by 6% since the previous quarter
The stock's P/B is 36% less than its 5-year quarterly average of 1.7 and 27% less than its last 4 quarters average of 1.5
The company's equity rose by 13% QoQ
The stock's P/S is 55% less than its 5-year quarterly average of 2.8 and 31% less than its last 4 quarters average of 1.8
Immucell's revenue has increased by 46% YoY and by 2.6% QoQ
Efficiency
How efficient is Immucell business performance
ICCC's return on sales has surged by 59% year-on-year and by 8% since the previous quarter
ICCC's ROIC is up by 41% year-on-year and by 4% since the previous quarter
The ROA is up by 38% year-on-year and by 5% since the previous quarter
The company's return on equity rose by 32% YoY and by 6% QoQ
Dividends
What is ICCC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ICCC.
Financial health
How did Immucell financials performed over time
ICCC's total assets is 146% higher than its total liabilities
ICCC's quick ratio has surged by 90% since the previous quarter and by 18% year-on-year
Immucell's current ratio has increased by 31% from the previous quarter but it has decreased by 13% YoY
Immucell's debt is 41% less than its equity
The company's equity rose by 13% QoQ
The company's debt to equity fell by 13% QoQ and by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.